secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0000950170-24-090727
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics Q2 2024 net loss widens to $126.4M; CASGEVY launch with 35+ ATCs
--------------------------------------------------------------------------------

- Net loss $126.4M vs $77.7M in Q2 2023; R&D expenses down to $80.2M from $101.6M.
- Cash, equivalents and securities $2.01B as of June 30, up from $1.70B at Dec 31, 2023.
- CASGEVY: >35 ATCs activated globally; ~20 patients have had cells collected as of mid-July.
- CTX112 CD19 CAR T Phase 1/2 trial opened for SLE; preliminary oncology data expected this year.
- Appointed Naimish Patel as CMO; promoted Julianne Bruno to COO and Susan Kim to SVP IR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024090727/0000950170-24-090727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024090727/crsp-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-090727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer